---
document_datetime: 2025-09-03 08:44:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.8725811
conversion_datetime: 2025-12-25 08:34:52.782442
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tepkinly

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                  |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/107/2 02409    | Periodic Safety Update EU Single assessment - epcoritamab                                      | 25/04/2025                          | 23/06/2025                                  | SmPC, Annex II and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/107/202409. |
| IB/0007              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 07/01/2025                          | 23/06/2025                                  | SmPC and PL                      |                                                                                                                                          |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/107/2 02403   | Periodic Safety Update EU Single assessment - epcoritamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/10/2024   | 12/12/2024   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/107/202403.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/10/2024   | 23/06/2025   | Annex II               |                                                                                                                                            |
| II/0001             | Extension of indication to include treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy for TEPKINLY, based on results from the indolent Non-Hodgkins Lymphoma (iNHL) expansion cohort of Study GCT3013-01, the First In Human (FIH) Phase 1/2 study in R/R B-NHL, with key supportive data from the Phase 1b/2 Study GCT3013-04 in Japanese subjects. Study GCT3013- 01 is an ongoing global, single-arm, Phase 1/2 study designed to evaluate epcoritamab as monotherapy in R/R B-NHL. As a consequence, sections 1, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.3, 6.4, 6.5 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Annex A is updated to clarify the pharmaceutical form for the 4mg/0.8ml strength. Version 2.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 27/06/2024   | 16/08/2024   | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-Var.No'                                                         |

<div style=\"page-break-after: always\"></div>

| R/0004    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                | 30/05/2024   | 17/07/2024   |                  | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Tepkinly, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                       | 08/04/2024   | 17/07/2024   | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0002/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 16/02/2024   | n/a          |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |